Enovis (NYSE:ENOV) Issues FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 3.100-3.250 for the period, compared to the consensus EPS estimate of 3.130. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Enovis Stock Performance

ENOV stock traded up $0.20 during trading on Friday, hitting $28.62. 627,019 shares of the company traded hands, compared to its average volume of 1,102,460. Enovis has a 1 year low of $25.47 and a 1 year high of $49.75. The company has a market cap of $1.64 billion, a PE ratio of -2.01 and a beta of 1.67. The stock’s 50-day simple moving average is $31.39 and its 200 day simple moving average is $31.50. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The business had revenue of $383.81 million for the quarter. On average, equities analysts expect that Enovis will post 2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ENOV. Wells Fargo & Company upped their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Needham & Company LLC lowered their price target on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Canaccord Genuity Group dropped their price objective on Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, UBS Group reduced their target price on Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Enovis currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.17.

Insider Buying and Selling

In other news, CEO Damien Mcdonald purchased 6,457 shares of the stock in a transaction dated Thursday, September 11th. The shares were purchased at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the purchase, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. The trade was a 6.71% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Bradley J. Tandy purchased 3,200 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average price of $31.41 per share, with a total value of $100,512.00. Following the completion of the transaction, the senior vice president directly owned 43,515 shares of the company’s stock, valued at $1,366,806.15. This represents a 7.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 12,157 shares of company stock worth $374,760. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENOV. California State Teachers Retirement System raised its position in shares of Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after buying an additional 621 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the last quarter. Empowered Funds LLC grew its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after acquiring an additional 749 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in Enovis by 10.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 15,207 shares of the company’s stock valued at $477,000 after acquiring an additional 1,487 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its stake in Enovis by 37.3% in the 2nd quarter. Corient Private Wealth LLC now owns 10,474 shares of the company’s stock worth $328,000 after purchasing an additional 2,847 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.